Implications of preclinical Alzheimer's disease biomarker disclosure for US policy and society-Reference-Cited by-同舟云学术

Implications of preclinical Alzheimer's disease biomarker disclosure for US policy and society

Published:2022-01 Issue:1 Volume:14 Page:
ISSN:2352-8729
Container-title:Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
language:en
Short-container-title:Alz & Dem Diag Ass & Dis Mo

Author:

Erickson Claire M.¹²,Clark Lindsay R.²³,Ketchum Fred B.⁴,Chin Nathaniel A.²,Gleason Carey E.²³,Largent Emily A.⁵

Affiliation:

1. Neuroscience & Public Policy Program University of Wisconsin‐Madison School of Medicine and Public Health Madison Wisconsin USA

2. Wisconsin Alzheimer's Disease Research Center Department of Medicine Division of Geriatrics & Gerontology University of Wisconsin‐Madison School of Medicine & Public Health Madison Wisconsin USA

3. Geriatric Research Education & Clinical Center William S. Middleton Memorial Veterans Hospital Madison Wisconsin USA

4. Department of Neurology University of Wisconsin School of Medicine and Public Health Madison Wisconsin USA

5. Department of Medical Ethics and Health Policy University of Pennsylvania Perelman School of Medicine Philadelphia Pennsylvania USA

Funder

National Institute on Aging

Publisher

Wiley

Subject

Psychiatry and Mental health,Neurology (clinical)

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/dad2.12339

Reference50 articles.

1. The Evolution of Preclinical Alzheimer’s Disease: Implications for Prevention Trials

2. Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

3. NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease

4. Association of Factors With Elevated Amyloid Burden in Clinically Normal Older Individuals

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ethical Considerations for Identifying Individuals in the Prodromal/Early Phase of Parkinson’s Disease: A Narrative Review;Journal of Parkinson's Disease;2024-07-04

2. Diagnosing Preclinical and Prodromal Neurodegenerative Diseases—The Clinical Is Political;JAMA Neurology;2024-05-01

3. 2024 Alzheimer's disease facts and figures;Alzheimer's & Dementia;2024-04-30

4. Perspectives of People At-Risk on Parkinson’s Prevention Research;Journal of Parkinson's Disease;2024-04-23

5. Creating an Unprotected Class: Addressing Legal Risks in the Era of Biologically-Defined Alzheimer’s Disease;Journal of Alzheimer's Disease;2024-03-05